Eledon Pharmaceuticals, Inc.
ELDNNASDAQ
Healthcare
Biotechnology
$3.17
+0.10(3.4%)
52W $1.39 – $4.36
Eledon Pharmaceuticals, Inc.
$190MMkt Cap
—Rev TTM
-$36MNI TTM
-5.1xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 18, 2026Eledon Pharmaceuticals, Inc. (ELDN), a clinical-stage immunology-focused biopharmaceutical company, reported a FY 2025 net loss of $45.6 million, widened from $36.2 million in 2024, driven by total operating expenses of $83.3 million including $66.3 million research and development and $17.0 million general and administrative. Other net income of $4.2 million was outweighed by a $33.4 million unfavorable change in fair...
Fundamentals
How The Business Makes Money
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Industry Biotechnology
Company Profile
CIK0001404281
ISINUS28617K1016
CUSIP28617K101
Phone949 238 8090
Address19900 MacArthur Boulevard, Irvine, CA, 92612, US
SEC EDGAR